AU2015279571A1 - Hepcidin and mini-hepcidin analogues and uses therof - Google Patents
Hepcidin and mini-hepcidin analogues and uses therof Download PDFInfo
- Publication number
- AU2015279571A1 AU2015279571A1 AU2015279571A AU2015279571A AU2015279571A1 AU 2015279571 A1 AU2015279571 A1 AU 2015279571A1 AU 2015279571 A AU2015279571 A AU 2015279571A AU 2015279571 A AU2015279571 A AU 2015279571A AU 2015279571 A1 AU2015279571 A1 AU 2015279571A1
- Authority
- AU
- Australia
- Prior art keywords
- absent
- lys
- ala
- arg
- cys
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462018382P | 2014-06-27 | 2014-06-27 | |
| US62/018,382 | 2014-06-27 | ||
| PCT/US2015/038370 WO2015200916A2 (en) | 2014-06-27 | 2015-06-29 | Hepcidin and mini-hepcidin analogues and uses therof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2015279571A1 true AU2015279571A1 (en) | 2017-02-02 |
Family
ID=54938965
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015279571A Abandoned AU2015279571A1 (en) | 2014-06-27 | 2015-06-29 | Hepcidin and mini-hepcidin analogues and uses therof |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20170313754A1 (https=) |
| EP (1) | EP3161164A4 (https=) |
| JP (1) | JP2017523959A (https=) |
| KR (1) | KR20170043509A (https=) |
| CN (1) | CN107075574A (https=) |
| AU (1) | AU2015279571A1 (https=) |
| CA (1) | CA2953721A1 (https=) |
| IL (1) | IL249692A0 (https=) |
| SG (1) | SG11201610799WA (https=) |
| WO (1) | WO2015200916A2 (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4944360B2 (ja) | 2001-05-25 | 2012-05-30 | アンスティテュ ナシオナル ド ラ サント エ ド ラ ルシュルシェ メディカル（アンセルム） | 鉄ホメオスタシスの障害を治療するための医薬品を製造するためのヘプシジンの使用 |
| DK2968443T3 (da) | 2013-03-15 | 2021-12-06 | Protagonist Therapeutics Inc | Hepcidinanaloger og anvendelser deraf |
| US12383518B2 (en) | 2013-11-03 | 2025-08-12 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Disulfide-masked pro-chelator compositions and methods of use |
| US11504346B2 (en) | 2013-11-03 | 2022-11-22 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Redox-activated pro-chelators |
| PT3143037T (pt) | 2014-05-16 | 2021-09-24 | Protagonist Therapeutics Inc | Antagonistas peptídicos tioéter de integrina alfa4beta7 |
| US9624268B2 (en) | 2014-07-17 | 2017-04-18 | Protagonist Therapeutics, Inc. | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| KR20170108936A (ko) | 2014-10-01 | 2017-09-27 | 프로타고니스트 테라퓨틱스, 인코포레이티드 | 신규한 α4β7 펩타이드 단량체 및 이량체 길항제 |
| EP3201217A4 (en) | 2014-10-01 | 2018-07-18 | Protagonist Therapeutics Inc. | Novel cyclic monomer and dimer peptides having integrin antagonist activity |
| US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| US20190002503A1 (en) | 2015-12-30 | 2019-01-03 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| AU2017205633A1 (en) * | 2016-01-08 | 2018-08-16 | La Jolla Pharmaceutial Company | Methods of administering hepcidin |
| WO2017165676A1 (en) | 2016-03-23 | 2017-09-28 | Protagonist Therapeutics, Inc. | METHODS FOR SYNTHESIZING α4β7 PEPTIDE ANTAGONISTS |
| CA3035234A1 (en) * | 2016-09-06 | 2018-03-15 | La Jolla Pharmaceutical Company | Methods of treating iron overload |
| JP2020502169A (ja) * | 2016-12-19 | 2020-01-23 | ラ ホヤ ファーマシューティカル カンパニーＬａ Ｊｏｌｌａ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏｍｐａｎｙ | ヘプシジンを投与する方法 |
| WO2018128828A1 (en) | 2016-12-23 | 2018-07-12 | Bayer Healthcare Llc | Novel hepcidin mimetics and uses thereof |
| US20200170971A1 (en) * | 2017-07-18 | 2020-06-04 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Disulfide-masked pro-chelator compositions and methods of use |
| EP3681900A4 (en) | 2017-09-11 | 2021-09-08 | Protagonist Therapeutics, Inc. | OPIOID AGONIST PEPTIDES AND THEIR USES |
| EP3749345A4 (en) * | 2018-02-08 | 2022-04-06 | Protagonist Therapeutics, Inc. | CONJUGATED HEPCIDIN MIMETICS |
| TW202019948A (zh) | 2018-07-12 | 2020-06-01 | 美商領導醫療有限公司 | 介白素-23受體之肽抑制劑及其治療發炎疾病之用途 |
| ES2934492T3 (es) | 2018-12-13 | 2023-02-22 | Global Blood Therapeutics Inc | Inhibidores de ferroportina y métodos de uso |
| CA3139209A1 (en) | 2019-05-07 | 2020-11-12 | Bayer Aktiengesellschaft | Masp inhibitory compounds and uses thereof |
| CN114341161A (zh) | 2019-07-10 | 2022-04-12 | 领导医疗有限公司 | 白细胞介素-23受体的肽抑制剂及其用于治疗炎症性疾病的用途 |
| US20210061872A1 (en) * | 2019-09-03 | 2021-03-04 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| CN114761013A (zh) * | 2019-09-27 | 2022-07-15 | 迪斯克医药公司 | 治疗骨髓纤维化和相关病症的方法 |
| US20220372136A1 (en) * | 2019-09-27 | 2022-11-24 | Disc Medicine, Inc. | Methods for treating anemia of chronic disease |
| AU2021209086A1 (en) | 2020-01-15 | 2022-08-04 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| HRP20250769T1 (hr) | 2020-01-15 | 2025-08-29 | Janssen Biotech, Inc. | Peptidni inhibitori receptora za interleukin-23 i njihova uporaba u liječenju upalnih bolesti |
| AU2021263818A1 (en) | 2020-04-28 | 2022-11-03 | Global Blood Therapeutics, Inc. | Cycloalkyl pyrimidines as ferroportin inhibitors |
| EP4142732B1 (en) | 2020-04-28 | 2026-04-22 | Global Blood Therapeutics, Inc. | Methods of use for pyrimidines as ferroportin inhibitors |
| EP4143197A1 (en) | 2020-04-28 | 2023-03-08 | Global Blood Therapeutics, Inc. | Thieno pyrimidines as ferroportin inhibitors |
| WO2021231798A1 (en) | 2020-05-13 | 2021-11-18 | Disc Medicine, Inc. | Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis |
| CN111560051B (zh) * | 2020-05-26 | 2022-11-25 | 大连工业大学 | 一种具有促铁吸收活性的虾源九肽及其应用 |
| CN115997130A (zh) * | 2020-07-02 | 2023-04-21 | 坦佩雷大学注册基金会 | 基于肾素的铁调素分析 |
| IL299530A (en) * | 2020-07-28 | 2023-02-01 | Protagonist Therapeutics Inc | Psidine is a conjugated mimetic |
| CN114252627A (zh) * | 2020-09-24 | 2022-03-29 | 首都医科大学附属北京世纪坛医院 | 尿液铁调素及其多肽片段在过敏性疾病中的应用 |
| AU2021383828A1 (en) | 2020-11-20 | 2023-07-06 | Janssen Pharmaceutica Nv | Compositions of peptide inhibitors of interleukin-23 receptor |
| AU2022249095A1 (en) * | 2021-04-01 | 2023-10-12 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| CA3220871A1 (en) * | 2021-06-14 | 2022-12-22 | Protagonist Therapeutics, Inc. | Hepcidin mimetics for treatment of hereditary hemochromatosis |
| WO2023288019A2 (en) | 2021-07-14 | 2023-01-19 | Janssen Biotech, Inc. | Lipidated peptide inhibitors of interleukin-23 receptor |
| CN115703826B (zh) * | 2021-08-03 | 2025-05-06 | 浙江大学 | 铁调素改造体及其应用 |
| EP4587034A1 (en) * | 2022-09-15 | 2025-07-23 | Migal Galilee Research Institute Ltd | Site-specific activation of regulatory t cells |
| WO2025224128A1 (en) | 2024-04-24 | 2025-10-30 | Institut National de la Santé et de la Recherche Médicale | Methods of treatment of iron overload associated diseases by administration hepcidin locally in the gut |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201307390A (zh) * | 2007-02-02 | 2013-02-16 | Amgen Inc | 海帕西啶（ｈｅｐｃｉｄｉｎ）、海帕西啶拮抗劑及使用方法 |
| CN101358201A (zh) * | 2007-07-31 | 2009-02-04 | 钱忠明 | 重组人铁调素腺病毒、其制备方法及应用 |
| CN101307085B (zh) * | 2007-08-01 | 2012-06-13 | 香港理工大学深圳研究院 | 抑制铁调素调节蛋白的siRNA、重组慢病毒及其应用 |
| GR1006896B (el) * | 2007-08-24 | 2010-07-20 | Ελληνικο Ινστιτουτο Παστερ, | Μεθοδος παραγωγης μιας πεπτιδικης ορμονης |
| CN102245626A (zh) * | 2008-12-05 | 2011-11-16 | 加利福尼亚大学董事会 | 微型铁调素肽及其使用方法 |
| WO2013086143A1 (en) * | 2011-12-09 | 2013-06-13 | The Regents Of The University Of California | Modified mini-hepcidin peptides and methods of using thereof |
| WO2011149942A2 (en) * | 2010-05-24 | 2011-12-01 | Children's Medical Center Corporation | Compositions and methods for plasma peptide analysis |
| DK2968443T3 (da) * | 2013-03-15 | 2021-12-06 | Protagonist Therapeutics Inc | Hepcidinanaloger og anvendelser deraf |
-
2015
- 2015-06-29 KR KR1020177002630A patent/KR20170043509A/ko not_active Withdrawn
- 2015-06-29 EP EP15812513.8A patent/EP3161164A4/en not_active Withdrawn
- 2015-06-29 AU AU2015279571A patent/AU2015279571A1/en not_active Abandoned
- 2015-06-29 JP JP2016575360A patent/JP2017523959A/ja not_active Withdrawn
- 2015-06-29 CN CN201580043057.2A patent/CN107075574A/zh active Pending
- 2015-06-29 CA CA2953721A patent/CA2953721A1/en not_active Abandoned
- 2015-06-29 WO PCT/US2015/038370 patent/WO2015200916A2/en not_active Ceased
- 2015-06-29 SG SG11201610799WA patent/SG11201610799WA/en unknown
- 2015-06-29 US US15/321,124 patent/US20170313754A1/en not_active Abandoned
-
2016
- 2016-12-21 IL IL249692A patent/IL249692A0/en unknown
-
2019
- 2019-06-12 US US16/439,435 patent/US20200017566A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2953721A1 (en) | 2015-12-30 |
| EP3161164A2 (en) | 2017-05-03 |
| US20170313754A1 (en) | 2017-11-02 |
| WO2015200916A2 (en) | 2015-12-30 |
| EP3161164A4 (en) | 2018-04-25 |
| US20200017566A1 (en) | 2020-01-16 |
| KR20170043509A (ko) | 2017-04-21 |
| CN107075574A (zh) | 2017-08-18 |
| IL249692A0 (en) | 2017-02-28 |
| JP2017523959A (ja) | 2017-08-24 |
| SG11201610799WA (en) | 2017-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12269856B2 (en) | Hepcidin analogues and uses thereof | |
| US20200017566A1 (en) | Hepcidin and mini-hepcidin analogues and uses therof | |
| US11472842B2 (en) | Analogues of hepcidin mimetics with improved in vivo half lives | |
| US12234300B2 (en) | Conjugated hepcidin mimetics | |
| EP3570864B1 (en) | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | |
| WO2022026633A1 (en) | Conjugated hepcidin mimetics | |
| WO2022212698A1 (en) | Conjugated hepcidin mimetics | |
| HK1220112B (en) | Hepcidin analogues and uses therof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |